Abstract
Aim
RegIV, a member of the Regenerating (REG) gene family, may be a marker for the prediction of resistance to 5-fluorouracil (5-FU)-based chemotherapy. However, the relationship between the intrinsic drug resistance of gastric cancer (GC) cells to 5-FU used alone (single FU) or in multidrug therapeutic regimens (5-FU combinations) and RegIV expression has not been investigated.
Methods
The patient cohort comprised 45 patients with primary GC. The chemoresistance of GC cells to therapeutic regimens consisting of single 5-FU or FU combinations was investigated using the ATP-tumor chemosensitivity assay. The level of RegIV mRNA transcripts was determined by real-time reverse transcriptase-PCR. RegIV expression was evaluated as a novel predictive biomarker for the intrinsic drug resistance of primary GC cells to single 5-FU or 5-FU combinations.
Results
Upregulation of RegIV mRNA transcripts was observed in 36 of the 45 tumor specimens and was positively correlated with the invasive depth of the tumor cells (p = 0.000), the clinical stages (p = 0.000) and the in vitro intrinsic drug resistance of primary GC cells to 5-FU (p = 0.000) or 5-FU combinations.
Conclusion
RegIV mRNA transcript level was strongly associated with the intrinsic resistance of GC cells to single 5-FU or 5-FU combinations, suggesting that RegIV may play an important role in the intrinsic resistance of GC cells to 5-FU and that targeted therapy against the RegIV gene could be applied to overcome 5-FU resistance in the treatment of GC.
Similar content being viewed by others
References
Treatment Architecture China: Gastric Cancer. KantarHealth and Draco Healthcare Consulting, LLC; 2009.
MattsonJack. CancerMPact. The Mattson Jack Group, Inc.; St. Louis, MO. 2009.
Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19:1893–1907.
Nomura S, Kaminishi M. Surgical treatment of early gastric cancer. Dig Surg. 2007;24:96–100.
Jain VK, Cunningham D, Chau I. Preoperative and postoperative chemotherapy for gastric cancer. Surg Oncol Clin N Am. 2012;21:99–112.
Dikken JL, van de Velde CJ, Coit DG, Shah MA, Verheij M, Cats A. Treatment of resectable gastric cancer. Therap Adv Gastroenterol. 2012;5:49–69.
Meyer HJ, Wilke H. Treatment strategies in gastric cancer. Dtsch Arztebl Int. 2011;108:698–705.
Pasini F, Fraccon AP, DE Manzoni G. The role of chemotherapy in metastatic gastric cancer. Anticancer Res. 2011;31:3543–3554.
Fedorenko IV, Paraiso KH, Smalley KS. Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochem Pharmacol. 2011;82:201–209.
Shekhar MP. Drug resistance: challenges to effective therapy. Curr Cancer Drug Targets. 2011;11:613–623.
Mackenzie M, Spithoff K, Jonker D. Systemic therapy for advanced gastric cancer: a clinical practice guideline. Curr Oncol. 2011;18:e202–e209.
Fujii M, Kochi M, Takayama T. Recent advances in chemotherapy for advanced gastric cancer in Japan. Surg Today. 2010;40:295–300.
Ling ZQ, Qi CJ, Lu XX, et al. Heterogeneity of chemosensitivity in esophageal cancer using ATP-tumor chemosensitivity assay. Acta Pharmacol Sin. 2012;33:401–406.
Koomen JM, Smalley KS. Using quantitative proteomic analysis to understand genotype specific intrinsic drug resistance in melanoma. Oncotarget. 2011;2:329–335.
Sumantran VN. Cellular chemosensitivity assays: an overview. Methods Mol Biol. 2011;731:219–236.
Blumenthal RD, Goldenberg DM. Methods and goals for the use of in vitro and in vivo chemosensitivity testing. Mol Biotechnol. 2007;35:185–197.
Kurbacher CM, Cree IA. Chemosensitivity testing using microplate adenosine triphosphate-based luminescence measurements. Methods Mol Med. 2005;110:101–120.
Quintieri L, Fantin M, Vizler C. Identification of molecular determinants of tumor sensitivity and resistance to anticancer drugs. Adv Exp Med Biol. 2007;593:95–104.
Violette S, Festor E, Pandrea-Vasile I, et al. Reg IV a new member of the regenerating gene family, is overexpressed in colorectal carcinomas. Int J Cancer. 2003;103:185–193.
Zhang Y, Lai M, Lv B, et al. Overexpression of Reg IV in colorectal adenoma. Cancer Lett. 2003;200:69–76.
Bishnupuri KS, Luo Q, Murmu N, Houchen CW, Anant S, Dieckgraefe BK. Reg IV activates the epidermal growth factor receptor/Akt/AP-1 signaling pathway in colon adenocarcinomas. Gastroenterology. 2006;130:137–149.
Li XH, Zheng Y, Zheng HC, et al. REG IV overexpression in an early stage of colorectal carcinogenesis: an immunohistochemical study. Histol Histopathol. 2010;25:473–484.
Heiskala K, Arola J, Heiskala M, Andersson LC. Expression of Reg IV and Hath1 in neuroendocrine neoplasms. Histol Histopathol. 2010;25:63–72.
Tamura H, Ohtsuka M, Washiro M, et al. Reg IV expression and clinicopathologic features of gallbladder carcinoma. Hum Pathol. 2009;40:1686–1692.
Hayashi T, Matsubara A, Ohara S, et al. Immunohistochemical analysis of Reg IV in urogenital organs: Frequent expression of Reg IV in prostate cancer and potential utility as serum tumor marker. Oncol Rep. 2009;21:95–100.
Sasahira T, Oue N, Kirita T, et al. Reg IV expression is associated with cell growth and prognosis of adenoid cystic carcinoma in the salivary gland. Histopathology. 2008;53:667–675.
Bishnupuri KS, Luo Q, Korzenik JR, et al. Dysregulation of Reg gene expression occurs early in gastrointestinal tumorigenesis and regulates anti-apoptotic genes. Cancer Biol Ther. 2006;5:1714–1720.
Oue N, Mitani Y, Aung PP, et al. Expression and localization of Reg IV in human neoplastic and non-neoplastic tissues: Reg IV expression is associated with intestinal and neuroendocrine differentiation in gastric adenocarcinoma. J Pathol. 2005;207:185–198.
Sentani K, Oue N, Tashiro T, et al. Immunohistochemical staining of Reg IV and claudin-18 is useful in the diagnosis of gastrointestinal signet ring cell carcinoma. Am J Surg Pathol. 2008;32:1182–1189.
Pankova-Kholmyansky I, Arber N. Reg IV can serve for early diagnosis and therapy. Cancer Biol Ther. 2007;6:123–124.
Oue N, Sentani K, Noguchi T, et al. Serum olfactomedin 4 (GW112, hGC-1) in combination with Reg IV is a highly sensitive biomarker for gastric cancer patients. Int J Cancer. 2009;125:2383–2392.
Yamagishi H, Fukui H, Sekikawa A, et al. Expression profile of REG family proteins REG Ialpha and REG IV in advanced gastric cancer: comparison with mucin phenotype and prognostic markers. Mod Pathol. 2009;22:906–913.
Gu Z, Rubin MA, Yang Y, et al. Reg IV, a promising marker of hormone refractory metastatic prostate cancer. Clin Cancer Res. 2005;11:2237–2243.
Yasui W, Oue N, Sentani K, Sakamoto N, Motoshita J. Transcriptome dissection of gastric cancer: identification of novel diagnostic and therapeutic targets from pathology specimens. Pathol Int. 2009;59:121–136.
Kuniyasu H, Oue N, Sasahira T, et al. Reg IV, enhances peritoneal metastasis in gastric carcinomas. Cell Prolif. 2009;42:110–121.
Mitani Y, Oue N, Matsumura S, et al. Reg IV is a serum biomarker for gastric cancer patients and predicts response to 5-fluorouracil-based chemotherapy. Oncogene. 2007;26:4383–4393.
Vanderlaag K, Wang W, Fayadat-Dilman L, et al. Regenerating islet-derived family member, 4 modulates multiple receptor tyrosine kinases and mediators of drug resistance in cancer. Int J Cancer. 2012;130:1251–1263.
Ling ZQ, Li P, Ge MH, et al. Hypermethylation-modulated down-regulation of CDH1 expression contributes to the progression of esophageal cancer. Int J Mol Med. 2011;27:625–635.
Bishnupuri KS, Luo Q, Sainathan SK, et al. Reg IV regulates normal intestinal and colorectal cancer cell susceptibility to radiation-induced apoptosis. Gastroenterology. 2010;138(2):616–626 (626.e1-2).
Glaysher S, Yiannakis D, Gabriel FG, et al. Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC). BMC Cancer. 2009;27:300.
Glaysher S, Cree IA. Cell sensitivity assays: the ATP-based tumor chemosensitivity assay. Methods Mol Biol. 2011;731:247–257.
Nakamura R, Saikawa Y, Wada N, et al. Retrospective analysis of treatment for advanced gastric cancer with peritoneal dissemination. Gan Kagaku Ryoho. 2007;34:1827–1831.
Yuan SQ, Zhou ZW, Liang YJ, et al. Correlation of chemosensitivity measured by histoculture drug response assay to expression of multidrug resistance genes and proteins in gastric cancer. Ai Zheng. 2009;28:337–343.
Acknowledgments
This research was partly supported by a grant from the Science and Technology General Project of Zhejiang Province (No. 2009C33143) and a grant from the Science and Technology Plan Projects of Zhejiang Provincial Medicine and Health (2009B029).
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ying, LS., Yu, JL., Lu, XX. et al. Enhanced RegIV Expression Predicts the Intrinsic 5-Fluorouracil (5-FU) Resistance in Advanced Gastric Cancer. Dig Dis Sci 58, 414–422 (2013). https://doi.org/10.1007/s10620-012-2381-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-012-2381-3